The usefulness of antibodies to the BRCA1 protein in detecting the mutated BRCA1 gene. An immunohistochemical study

A Pérez-Vallés, M Martorell-Cebollada, E Nogueira-Vázquez, J A García-García, E Fuster-Diana

Abstract

Aim—To assess the value of immunohistochemistry in discriminating between BRCA1 associated and non-BRCA1 associated breast tumours.

Methods—Four commercially available anti-BRCA1 antibodies were used on 45 paraffin wax embedded tumoral samples from patients with (seven of 45) and without (38 of 45) BRCA1 germline mutations. In all patients, the BRCA1 gene had been studied previously by means of the protein truncation test (PTT), conformational sensitive gel electrophoresis (CSGE), and direct sequencing of genomic DNA. Immunohistochemistry was carried out using the standard avidin-biotin immunoperoxidase method. Antigen retrieval was carried out by means of microwave pretreatment or autoclaving. The antibody panel used comprised D-20 (1/500), I-20 (1/100), K-18 (1/100), and MS110 (Ab-1; 1/50).

Results—No immunohistochemical differences in BRCA1 protein expression were found between cases with and without BRCA1 germline mutations. All positive cases showed predominantly cytoplasmic staining, in both tumoral and non-tumoral cells, with the polyclonal antibodies D-20, I-20, and K-18. After heating pretreatment both nuclear and cytoplasmic staining were found in tumoral and non-tumoral cells with the I-20 antibody. Only the monoclonal antibody MS110 showed a predominantly nuclear staining after microwave oven treatment.

Conclusions—Commercially available BRCA1 antibodies lack the specificity required to identify the BRCA1 protein and thus are not useful for establishing differences between familial and sporadic breast tumours, or between BRCA1 associated and non-BRCA1 associated breast tumours.

(J Clin Pathol 2001;54:476-480)

Keywords: BRCA1; breast carcinoma; immunohistochemical study

BRCA1 is a large gene with a coding region of 5.5 kb, expanded in 24 exons, and a total mRNA size of approximately 80 kb, which is probably regulated by steroid hormones, oestrogen and progesterone.^{5,6} The protein has a RING finger domain at its N-terminus³ and a BRCT motif at its C-terminus,⁷ which functions as a transactivator.^{8,9}

The function of the BRCA1 protein is not fully elucidated but it probably plays an important role in DNA repair, apoptosis, or cell cycle arrest, interacting with p53 and RAD51 in response to DNA damage.¹⁰⁻¹³

There is much controversy with regard to the importance and localisation of BRCA1 protein expression. Chen *et al* reported that the BRCA1 protein is found in the nuclei of normal epithelial cells, but is aberrantly located in the cytoplasm of malignant mammary cells.¹⁴ In contrast, Scully *et al* found the BRCA1 protein in the nuclei of both normal and malignant cells.¹⁵ Jensen *et al* reported that BRCA1 is located in the cytoplasm and the cell membrane,¹⁶ whereas Coene *et al* proposed that it is located in cytoplasmic tube-like invaginations in the nucleus.¹⁷ These contradictory results on the location of the BRCA1 protein could result from differences in the specificity of the antibodies used, the different fixation methods used, and the presence of splice variant isoforms of the BRCA1 protein in tumours.

Immunohistochemical studies on formalin fixed, paraffin wax embedded tumours have demonstrated a loss or reduction of protein expression not only in BRCA1 associated breast carcinomas but also in non-BRCA1 associated familial and sporadic breast carcinomas.¹⁸⁻²⁰

Although the BRCA1 gene is not mutated in sporadic breast carcinomas,³ the loss or reduction of BRCA1 protein expression (as detected by immunohistochemistry)²⁰ and the high frequency of LOH^{21,22} indicate that the BRCA1 gene probably features in the genesis of sporadic breast cancer through a mechanism other than mutation.

In our study, we evaluate from a practical point of view the applicability and value of four different commercially available anti-BRCA1 antibodies (polyclonal D-20, I-20, and K-18 and monoclonal MS110) to discriminate between BRCA1 associated and non-BRCA1 associated tumours. We performed an immunohistochemical study on formalin fixed, paraffin wax embedded tumour samples from 45 patients with sporadic and inherited breast

Department of
Pathology, Hospital
General Universitario,
Avda. Tres Cruces, s/n,
46014 Valencia, Spain
A Pérez-Vallés
M Martorell-Cebollada
E Nogueira-Vázquez
J A García-García

Department of
Surgery, Hospital
General Universitario
E Fuster-Diana

Correspondence to: Dr
Pérez-Vallés
apv_comv@comv.es

Accepted for publication
20 November 2000

BRCA1 is a putative tumour suppressor gene^{1,2} linked to breast cancer in families with dominant inheritance of the disease.³ Many tumours with germline BRCA1 mutations display loss of heterozygosity (LOH)⁴ at this locus, with loss of the wild-type BRCA1 allele, indicating a role for BRCA1 as a tumour suppressor gene.

Table 1 Clinicopathological results

	BRCA1+ (n = 7)	BRCA1- (n = 38)	
		Familial cases (n = 16)	Sporadic cases (n = 22)
Group at risk (family history)			
High risk	7	10	
Low risk	0	6	
Age at diagnosis (years)			
≤45	5	6	14
>45	2	10	8
Tumour size (cm)			
T1 (≤2)	3	8	8
T2 (2–5)	4	4	10
T3 (≥5)	0	4	4
TNM stage			
I	2	8	4
II	5	3	7
III	0	5	11
Histological type (WHO)			
Invasive ductal carcinoma	3	12	19
Medullary carcinoma	4	1	3
Invasive lobular carcinoma	0	2	0
Mucinous carcinoma	0	1	0
Histological grade (Bloom and Richardson, Nottingham)			
Grade I	0	7	7
Grade II	2	7	12
Grade III	5	2	3
Axillary lymph node status			
Positive	1	5	13
Negative	6	11	9
Oestrogen receptor			
Positive (≥10 fmol/mg)	1	6	16
Negative (<10 fmol/mg)	6	10	6
Overall free survival (years)			
≤5	4	9	14
>5	3	7	8

Oestrogen receptor status was studied by enzyme immunoanalysis.

cancer, in whom germline mutations of the BRCA1 gene had been studied previously by means of the protein truncation test (PTT), conformational sensitive gel electrophoresis (CSGE), and direct sequencing of genomic DNA.

Methods

In total, 45 patients with both sporadic (n = 22) and familial (n = 23) breast cancer were selected. Familial cases had been stratified previously into high and low risk susceptibility groups according to the criteria of Hartmann *et al.*²³ Clinicopathological data were available in all cases (table 1). All tumours were histologically classified according to the WHO criteria²⁴ and were graded according to the Nottingham modification²⁵ of Bloom and Richardson.

A complete gene study in search of BRCA1 germline mutations had been carried out previously by means of PTT, CSGE, and direct sequencing of genomic DNA.

Table 2 BRCA1 mutations and immunostaining

Sample	Mutation	Codon	Exon	Coding effect	Immunostaining							
					D-20		I-20		K-18		MS110	
					N	C	N	C	N	C	N	C
Case 1	1623del5	541	11	Frameshift	–	++	–	++	–	++	–	–
Case 2	1623del5	541	11	Frameshift	–	+++*	+	++	–	–	++	–
Case 3	185delAG	61	2	Frameshift	–	++	+	++	–	++	–	–
Case 4	3450del4	1150	11	Frameshift	–	++	–	++	–	–	–	–
Case 5	3450del4	1150	11	Frameshift	–	++	+	++	–	–	+	–
Case 6	3450del4	1150	11	Frameshift	–	+++*	++	++	–	–	+	–
Case 7	3450del4	1150	11	Frameshift	–	++	++	++	–	+	++	–

Location of immunogen (amino acid): D-20, N-terminal (aa 2–21); I-20, C-terminal (aa 1826–46); K-18, N-terminal (aa 70–89); MS110, N-terminal (aa 1–304).

Antigen retrieval: D-20, I-20, and K-18, autoclaving; MS110, microwave.

Staining: C, cytoplasmic staining; N, nuclear staining; *membrane pattern.

The antibody panel used comprised the polyclonal D-20, I-20, and K18 antibodies from Santa Cruz Biotechnologies (Santa Cruz, California, USA) and the monoclonal MS110 (Ab-1) antibody from Oncogene Research Products (Cambridge, Massachusetts, USA).

Immunohistochemistry was performed on formalin fixed, paraffin wax embedded samples using the standard avidin–biotin immunoperoxidase method. Two different methods were used for antigen retrieval: autoclaving in 0.01 M sodium citrate at 121°C, 15 pounds/square inch for 30 minutes (for the polyclonal antibodies) and heating in a microwave oven at 500 W for 20 minutes in citrate buffer (for the monoclonal antibody). Slides were then incubated with the primary antibodies D-20 (1/500), I-20 (1/100), K18 (1/100), and MS110 (Ab-1; 1/50) and diluted with phosphate buffered saline (PBS) containing 0.5% Triton-X100 (vol/vol). Fixed, paraffin wax embedded myometrium served as a positive control, whereas similarly treated spleen tissue served as a negative control for the polyclonal antibodies, according to Jarvis and colleagues²⁶; the Ab-1 antibody was probed in normal skin and the staining of the basal epithelial cells served as a positive control. The negative control in this case was obtained by omitting the antibody.

Tumours with cytoplasmic and/or nuclear staining were considered positive. The proportion of stained cells was scored as follows: 0 (no staining), + (less than 25% of tumoral cells stained), and ++ (more than 25% of tumoral cells stained).

Results

Table 1 shows the clinicopathological results. Briefly, tumours from patients with BRCA1 mutations were mostly medullar carcinomas, had a high histological grade, and were oestrogen receptor negative.

All patients with BRCA1 germline mutations were in the “familial” group and belonged to high risk families. Three different BRCA1 germline mutations were found, namely: 1623del5 (two patients), 3450del4 (four patients), and 185delAG (one patient). All resulted in truncated proteins.

Table 2 lists the mutations found and their coding effects.

Figure 1 Ab-1 negative staining in a familial breast cancer from a patient without BRCA1 mutations. Note the positive staining in stromal lymphocytes surrounding tumoral cells.

IMMUNOHISTOCHEMICAL STUDY

Staining was heterogeneous in intensity and localisation (cytoplasmic *v* nuclear), mainly as a result of the antibody and the antigen retrieval method used.

After autoclaving, nuclear staining was negative in tumoral cells from patients with and without BRCA1 mutations with the D-20 and K-18 polyclonal antibodies.

Twenty cases failed to show nuclear staining with the I-20 polyclonal antibody: 18 were from patients without BRCA1 mutations and corresponded to five familial and 13 sporadic breast tumours; the other two (cases 1 and 4) were from patients with BRCA1 germline mutations 1623del5 and 3450del4. Four tumours from patients carrying the same mutations (case 2 and cases 5, 6, and 7) showed intense nuclear staining with this same antibody.

After microwave pretreatment, 24 tumours did not show nuclear staining with the MS110 monoclonal antibody (fig 1); 21 were from patients without BRCA1 germline mutations and corresponded to 10 familial and 11 sporadic breast tumours; the other three (cases 1, 3, and 4) were from patients with BRCA1 germline mutations 1623del5, 185delAG, and 3450del4. The remaining four tumours, however, from patients with the 1623del5 (case 2)

Figure 2 Ab-1 nuclear staining in familial breast cancer cases from patients (A) with and (B) without BRCA1 germline mutations.

Figure 3 Membrane staining pattern with the D-20 antibody in a familial breast cancer from a patient with BRCA1 mutation.

and 3450del4 (cases 5, 6, and 7) mutations, showed nuclear staining; hence, the presence or absence of nuclear staining was not related to the presence or absence of BRCA1 germline mutations (fig 2), or to the type of BRCA1 mutation present.

Cytoplasmic staining was positive in all 45 cases with the D-20 and I-20 polyclonal antibodies, in contrast to the staining pattern found with the MS110 monoclonal antibody, which was predominantly nuclear, with the exception of one sample (case 24) without BRCA1 mutations. The K-18 polyclonal antibody gave positive results for cytoplasmic staining in 10 patients (1, 3, and 7 all of whom had BRCA1 mutations). As with the nuclear staining, no correlation was found between staining and the presence or absence of BRCA1 germline mutations.

The cytoplasmic staining pattern was predominantly diffuse. A membrane staining pattern was also seen in 19 patients (patients 2 and 6 had BRCA1 mutations) when the D-20 antibody was used (fig 3); in addition, one patient (case 11) showed a granular cytoplasmic staining with the K-18 antibody (data not shown).

Results in non-tumoral cells present within the samples were similar to those observed in tumoral cells. No nuclear staining was seen with the D-20 and K-18 antibodies and only cytoplasmic staining was seen in these cases. We found cytoplasmic and nuclear staining in seven patients with the I-20 antibody, and two of these patients (cases 1 and 5) had BRCA1 germline mutations. Finally, with the MS110 antibody, non-tumoral cells showed a predominantly nuclear staining pattern in all patients (data not shown).

Tables 2 and 3 show the results of the immunohistochemical study. We found no correlation between BRCA1 staining and other prognostic factors, such as oestrogen receptor or axillary lymph node status. Only tumoral size (tumours ≥ 4 cm) and certain histological types (medullar carcinoma) appeared to correlate with the absence of BRCA1 staining, whereas most of the grade I tumours were positive.

Discussion

In our study, we describe the use of immunohistochemistry on routinely processed, neutral formalin fixed and paraffin wax embedded

Table 3 BRCA1 immunostaining in BRCA1 negative cases

Antibody	Familial cases (n = 16)				Sporadic cases (n = 22)			
	Nuclear staining		Cytoplasmic staining		Nuclear staining		Cytoplasmic staining	
	Positive	Negative	Positive	Negative	Positive	Negative	Positive	Negative
D-20	16	16	–	–	22	22	–	–
I-20	11	5	15	1	9	13	22	–
K-18	16	5	11	–	22	2	20	–
Ab-1	6	10	–	16	11	11	1	21

tumours from 45 patients with breast carcinoma (23 familial, 22 sporadic).

The BRCA1 gene had been studied previously in all cases, and three different BRCA1 germline mutations (185delAG, 1623del5, and 3450del4) were found in seven patients from the familial group; all were frameshift mutations resulting in truncated proteins.

There is controversy regarding the size and localisation of the BRCA1 protein, mainly as a result of differences in fixation,^{15–17} the antigen retrieval method used, and the specificity of anti-BRCA1 antibodies.^{27–28} Using autoclaving and microwave antigen retrieval methods, we found that of all of the antibodies tested (D-20, I-20, K-18, and MS110), only MS110 (Ab-1) produced consistent results on routinely processed material.

Using the D-20 and K-18 antibodies, we found cytoplasmic staining only, the nucleus being constantly non-immunoreactive either in cancer or normal mammary gland cells in all samples tested. This agrees with data from a previous report²⁹ in which only cytoplasmic staining was seen using polyclonal antibodies D-20, I-20, K-18, and C-20 on paraffin wax embedded samples. Our results differ from those of Jarvis,²⁶ who found differences in nuclear staining of tumour cells with the D-20 antibody, the cytoplasm being positive in all sporadic breast cancers tested.

Using the C-terminal I-20 polyclonal antibody, we found no differences in staining between tumoral and non-tumoral mammary epithelial cells. Uniform cytoplasmic staining was seen in all samples with heterogeneous nuclear staining. Data have been published demonstrating I-20 false positive immunostaining using cell lines lacking the C-terminal portion of the BRCA1 protein¹⁹; furthermore, the I-20 antibody probably recognises proteins other than BRCA1,³⁰ or products of alternative splicing of the BRCA1 gene.¹⁸

Although these polyclonal antibodies (D-20, I-20, and K-18) were valid for immunoprecipitation studies, their value for immunohistochemistry on frozen or paraffin wax embedded samples has been questioned.¹⁸

In our study, the monoclonal antibody MS110 (Ab-1)¹⁵ appeared to give the most accurate, reliable, and reproducible results when used on formalin fixed, paraffin wax embedded material.^{19–20}

The MS110 antibody reacts with the N-terminal portion of the BRCA1 protein only after antigen retrieval by heating (microwave or autoclaving), producing an almost exclusively nuclear staining pattern in normal mammary cells.^{15–20}

Using the MS110 antibody and antigen retrieval with a microwave oven, we observed complete loss of nuclear staining in three of the seven familial BRCA1 associated breast cancers. Similar results were seen by Yoshikawa *et al.*,¹⁹ who found a loss of nuclear signal in seven of the 19 BRCA1 associated breast carcinomas studied.

As expected, no signal was detected in the malignant cells in the only tumour containing the BRCA1 185delAG mutation, which results in the deletion of most of the protein, including the Ab-1 epitope. No nuclear signal was seen in tumour cells from patients carrying the 1623del5 and 3450del4 BRCA1 germline mutations, in agreement with previous reports in which the expression of BRCA1 mRNA in BRCA1 associated cancer was found to be low, regardless of the type of mutation,^{19–31} because loss of the BRCA1 protein occurs irrespective of the position of the mutation in the BRCA1 gene.²⁰

Some data from previous studies have shown that the BRCA1 protein is present in the cytoplasm. Splice variant isoforms that lack exon 11 along with the nuclear localisation signal are located exclusively in the cytoplasm.^{29–32} However, we found no cytoplasmic staining with the MS110 antibody in the 45 breast cancers that we tested.

We found that different patients were carriers of the same truncating mutation: 1623del5 (patients 1 and 2) and 3450del4 (patients 4–7). Of particular interest was the fact that with the MS110 antibody negative nuclear staining was seen in patients 1 and 4 only, and staining was positive in the remainder of the tumours. The expression of BRCA1 mRNA is directly related to the number of wild-type alleles.³³ The relatively high amounts of BRCA1 protein that we detected immunohistochemically in some of the tumours with truncated BRCA1 proteins, and the discrepancies between tumours carrying the same mutation, may result either from the retention of the wild-type allele or heterozygosity among cancer cells.^{19–33} Results reported by Yoshikawa and colleagues¹⁹ support the idea that MS-110 could be useful in prescreening tumours for BRCA1 mutations, mainly because of the high detection rate (seven of nineteen) of alterations in the BRCA1 gene product in BRCA1 associated breast cancers. Our results (three of seven) are quite similar to those of Yoshikawa¹⁹ when only the familial BRCA1 associated breast cancers are compared. Applying these criteria, our apparent detection rate of BRCA1 mutations using the MS110 antibody is highest in familial (62.5%) and sporadic (50%) non-BRCA1 associated breast carcinomas. The

presence or absence of BRCA1 germline mutations was objectively demonstrated in all patients after the study of the BRCA1 gene by PTT, CSGE, and direct sequencing of genomic DNA.

Taylor *et al* reported the absence of nuclear and cytoplasmic BRCA1 expression in 142 non-familial breast cancers studied by immunohistochemistry, and loss of nuclear BRCA1 expression in 19% of the cases, indicating that BRCA1 plays a role in sporadic cancers.²⁰ Similar results have been reported in other immunohistochemical studies on sporadic, non-inherited breast cancer that used the MS110 (Ab-1) antibody, with a reduction in nuclear BRCA1 expression in 27%,¹⁹ 20%,³⁴ and 43.5%¹⁸ of the tumours tested.

A reduction of BRCA1 protein expression in sporadic carcinomas has been associated with high histological grade tumours,¹⁸ overexpression¹⁹ and loss³⁴ of the c-erb-B-2 protein, and high proliferative phenotype, perhaps related to truncations at the N-terminal and C-terminal portions of the BRCA1 protein.²⁶ We did not find a relation between the loss of nuclear staining and histological grade, tumour type, other clinicopathological data, or expression of oestrogen or progesterone receptors, p53, cathepsin D, c-erbB-2, and bcl-2 using immunohistochemistry (data not shown).

These data are consistent with the observation that BRCA1 mRNA values are decreased in sporadic breast cancers³⁵ and in breast cancer cell lines such as MCF-7.³³ Concentrations of the BRCA1 protein are also decreased in mammary tumours compared with matched normal breast tissue,³⁶ implying multiple mechanisms of BRCA1 expression downregulation in these tumours. Other data suggest that the reduced expression of the BRCA1 protein might play an important role in mammary carcinogenesis in sporadic cancer, and that mechanisms other than mutation,^{19, 21} in particular LOH,²⁹ might be involved in the reduced expression of the BRCA1 protein. Taken together, our data support the notion that the N-terminal specific MS110 antibody is not useful in prescreening BRCA1 mutations because it has a lower rate of detection in breast tumours from patients carrying a BRCA1 gene mutation than in tumours, both familial (65%) or sporadic (50%), from patients without BRCA1 germline mutations. This fact, together with the inconsistency in immunohistochemical results among patients carrying the same truncating BRCA1 mutation, points to the non-specificity of the MS110 antibody in the prescreening of BRCA1 associated mammary cancers.

- 1 Holt JT, Thompson ME, Szabo C, *et al*. Growth retardation and tumor inhibition by BRCA1. *Nat Genet* 1996;12:298-302.
- 2 Rao VN, Shao N, Ahmad M, *et al*. Antisense RNA to the putative tumor suppressor gene BRCA1 transforms mouse fibroblasts. *Oncogene* 1996;12:523-8.
- 3 Miki Y, Swensen J, Shattuck-Eidens D, *et al*. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. *Science* 1994;266:66-71.
- 4 Smith SA, Easton DF, Evans DGR, *et al*. Allele losses in the region 17q12-21 in familial breast and ovarian cancer involve the wild-type chromosome. *Nat Genet* 1992;2:128-31.
- 5 Gudas JM, Nguyen H, Li T, *et al*. Hormone-dependent regulation of BRCA1 in human breast cancer cells. *Cancer Res* 1995;55:4561-5.

- 6 Fan S, Wang J-A, Yuan R, *et al*. BRCA1 inhibition of estrogen receptor signaling in transfected cells. *Science* 1999;284:1354-6.
- 7 Koonin EV, Altschul SF, Bork P. BRCA1 protein products. Functional motifs. *Nat Genet* 1996;13:266-8.
- 8 Chapman MS, Verma IM. Transcriptional activation by BRCA1. *Nature* 1996;382:678-9.
- 9 Monteiro AN, August A, Hanafusa H. Evidence for a transcriptional activation function of BRCA1 C-terminal region. *Proc Natl Acad Sci U S A* 1996;93:13595-9.
- 10 Kote-Jarai Z, Eeles RA. BRCA1, BRCA2 and their possible function in DNA damage response. *Br J Cancer* 1999;81:1099-102.
- 11 Gowen LC, Avrutska AV, Latour AM, *et al*. BRCA1 required for transcription-coupled repair of oxidative DNA damage. *Science* 1998;281:1009-12.
- 12 Shao N, Chai YL, Shyam E, *et al*. Induction of apoptosis by the tumor suppressor protein BRCA1. *Oncogene* 1996;13:1-7.
- 13 Cortez D, Wang Y, Qin J, *et al*. Requirement of ATM-dependent phosphorylation of BRCA1 in the DNA damage response to double-strand breaks. *Science* 1999;286:1162-6.
- 14 Chen Y, Chen C-F, Riley DJ, *et al*. Aberrant subcellular localization of BRCA1 in breast cancer. *Science* 1995;270:789-91.
- 15 Scully R, Ganesan S, Brown M, *et al*. Location of BRCA1 in human breast and ovarian cancer cells. *Science* 1996;272:123-5.
- 16 Jensen RA, Thompson ME, Jetton TL, *et al*. BRCA1 is secreted and exhibits properties of a granin. *Nat Genet* 1996;12:303-8.
- 17 Coene E, Van-Oostveldt P, Willems K, *et al*. BRCA1 is localized in cytoplasmic tube-like invaginations in the nucleus. *Nat Genet* 1997;16:122-4.
- 18 Wilson CA, Ramos L, Villaseñor MR, *et al*. Localization of human BRCA1 and its loss in high-grade, non-inherited breast carcinomas. *Nat Genet* 1999;21:236-40.
- 19 Yoshikawa K, Honda K, Inamoto T, *et al*. Reduction of BRCA1 protein expression in Japanese sporadic breast carcinomas and its frequent loss in BRCA1-associated cases. *Clin Cancer Res* 1999;5:1249-61.
- 20 Taylor J, Lymboura M, Pace PE, *et al*. An important role for BRCA1 in breast cancer progression is indicated by its loss in a large proportion of non-familial breast cancers. *Int J Cancer* 1998;79:334-42.
- 21 Bièche I, Nogués C, Lidereau R. Overexpression of BRCA2 gene in sporadic breast tumours. *Oncogene* 1999;18:5232-8.
- 22 Gonzalez R, Silva JM, Dominguez G, *et al*. Detection of loss of heterozygosity at RAD51, RAD52, RAD54 and BRCA1 and BRCA2 loci in breast cancer: pathological correlations. *Br J Cancer* 1999;81:503-9.
- 23 Hartmann LC, Schaid DJ, Woods JE, *et al*. Efficacy of bilateral prophylactic mastectomy in women with a family history of breast cancer. *N Engl J Med* 1999;340:77-84.
- 24 Azzopardi JG, Chepik OF, Hartmann WH, *et al*. The World Health Organisation histological typing of breast tumors—second edition. *Am J Clin Pathol* 1982;78:113-23.
- 25 Frierson HF, Wolber RA, Berean KW, *et al*. Interobserver reproducibility of the Nottingham modification of the Bloom and Richardson histologic grading scheme for infiltrating ductal carcinoma. *Am J Clin Pathol* 1995;103:195-8.
- 26 Jarvis EM, Kirk JA, Clarke CL. Loss of nuclear BRCA1 expression in breast cancers is associated with a highly proliferative tumor phenotype. *Cancer Genet Cytogenet* 1998;101:109-15.
- 27 Wilson CA, Payton MN, Pekar SK, *et al*. BRCA1 protein products: antibody specificity. *Nat Genet* 1996;13:264-5.
- 28 Bernard-Gallon DJ, Crespin NC, Maurizis JC, *et al*. Cross-reaction between antibodies raised against the last 20 C-terminal amino acids of BRCA1 (C-20) and human EGF and EGF-R in MCF 10a human mammary epithelial cell line. *Int J Cancer* 1997;71:123-6.
- 29 Bernard-Gallon DJ, Peffault de Latour M, Rio PG, *et al*. Subcellular localization of BRCA1 protein in sporadic breast carcinoma with or without allelic loss of BRCA1 gene. *Int J Oncol* 1999;14:653-61.
- 30 Wilson CA, Payton MN, Elliott GS, *et al*. Differential subcellular localization, expression and biological toxicity of BRCA1 and the splice variant BRCA1-Δ11b. *Oncogene* 1997;14:1-16.
- 31 Kainu T, Kononen J, Johansson O, *et al*. Detection of germline BRCA1 mutations in breast cancer patients by quantitative messenger RNA in situ hybridization. *Cancer Res* 1996;56:2912-15.
- 32 Thakur S, Zhang HB, Peng Y, *et al*. Localization of BRCA1 and a splice variant identifies the nuclear localization signal. *Mol Cell Biol* 1997;17:444-52.
- 33 Ribieras S, Magdinier F, Leclerc D, *et al*. Abundance of BRCA1 transcripts in normal breast tissue and lymphoblastoid cell lines carrying BRCA1 germ-line alterations. *Int J Cancer* 1997;73:715-18.
- 34 Lee W-Y, Jin Y-T, Chang T-W, *et al*. Immunolocalization of BRCA1 protein in normal breast tissue and sporadic invasive ductal carcinomas: a correlation with other biological parameters. *Histopathology* 1999;34:106-12.
- 35 Thompson ME, Jensen RA, Obermiller PS, *et al*. Decreased expression of BRCA1 accelerates growth and is often present during sporadic breast cancer progression. *Nat Genet* 1995;9:444-50.
- 36 Rio PG, Maurizis J-C, Peffault de Latour M, *et al*. Quantification of BRCA1 protein in sporadic breast carcinoma with or without loss of heterozygosity of the BRCA1 gene. *Int J Cancer* 1999;80:823-6.